scholarly journals Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer

2018 ◽  
Vol 7 (4) ◽  
pp. 1183-1193 ◽  
Author(s):  
Tomi Akinyemiju ◽  
Swati Sakhuja ◽  
John Waterbor ◽  
Maria Pisu ◽  
Sean F. Altekruse
Keyword(s):  
Prostate Cancer ◽  
De Novo ◽  
Ethnic Disparities ◽  
Survival Outcomes ◽  
Racial Ethnic

Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER-CAHPS study

2022 ◽  
Author(s):  
Stephanie Navarro ◽  
Xiaohui Hu ◽  
Aaron Mejia ◽  
Carol Y. Ochoa ◽  
Trevor A. Pickering ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Ethnic Disparities ◽  
Patient Experiences ◽  
Racial Ethnic

scholarly journals Optimal Treatment for Patients with Oligometastatic Prostate Cancer

2021 ◽  
pp. 1-10
Author(s):  
Bulent Cetin ◽  
Chiara A. Wabl ◽  
Ozge Gumusay
Keyword(s):  
Prostate Cancer ◽  
Metastatic Disease ◽  
De Novo ◽  
Optimal Treatment ◽  
Survival Outcomes ◽  
Appendicular Skeleton ◽  
Oncological Outcomes ◽  
Oligometastatic Prostate Cancer

Oligometastatic prostate cancer (PCa) can be defined as cancer with a limited number of metastases, typically fewer than 5 lesions, and involves lesions contained within the axial versus the appendicular skeleton. Patients can present with de novo oligometastatic, oligorecurrent, or oligoprogressive PCa. Oligometastatic PCa patients demonstrate considerable improvements in survival outcomes, with a better prognosis than patients with extensive metastatic disease. However, the management of patients that present with nonsymptomatic oligometastatic PCa remains difficult. In the oligometastatic setting, the benefit of local therapies such as prostatectomy and radiotherapy on survival outcomes is an intriguing topic; however, their impact on oncological outcomes is still unknown.

RACIAL/ETHNIC DISPARITIES IN THE TREATMENT OF LOCALIZED/REGIONAL PROSTATE CANCER

2004 ◽  
Vol 171 (4) ◽  
pp. 1504-1507 ◽  
Author(s):  
WILLIE UNDERWOOD ◽  
SONYA DeMONNER ◽  
PETER UBEL ◽  
ANGELA FAGERLIN ◽  
MARTIN G. SANDA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ethnic Disparities ◽  
Racial Ethnic

Racial/ethnic disparities in estrogen and progesterone receptor phenotype and survival outcomes.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 54-54
Author(s):  
Raji Shameem ◽  
Muhammad S Hamid ◽  
Niket Sonpal ◽  
Anita Pudusseri ◽  
Robert Graham ◽  
...  
Keyword(s):  
Progesterone Receptor ◽  
Ethnic Groups ◽  
Prognostic Significance ◽  
Ethnic Disparities ◽  
Survival Outcomes ◽  
Improved Outcomes ◽  
Poor Outcomes ◽  
Receptor Phenotype ◽  
Racial Ethnic ◽  
Estrogen And Progesterone Receptor

54 Background: The incidence of estrogen receptor (ER) and progesterone receptor (PR) phenotypes varies among different racial/ethnic groups. However, the prognostic significance of specific ER/PR phenotypes on survival in racial/ethnic groups including Asians has not been reported. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to identify invasive breast cancer cases from 1988 to 2009. Groups included were: “Non-Hispanic Whites (NHW)”, “Blacks”, “Filipinos”, “Chinese”, “Japanese”, “Koreans”, “Vietnamese”, and “Asian Indian/Pakistanis (AIP)”. Cases were grouped according to ER/PR phenotype (ER+/PR+, ER-/PR-, ER+/PR-, ER-/PR+). The Kruskall-Wallis test, and the Z test were employed to examine for differences between racial/ethnic groups. Multivariate Cox proportional analyses were used to establish the weight of the age adjusted ER/PR phenotype on the prognostic significance contributing to survival. Results: In comparison to NHW, ER+/PR+ status was associated with poor outcomes in blacks (HR: 1.814, p < 0.01), however improved outcomes were seen in Chinese (HR: 0.759, p <0.01), Vietnamese (HR: 0.755, p < 0.01), AIP (HR: 0.751; p < 0.01), Koreans (HR: 0.661, p < 0.01) and Japanese (HR: 0.608, p < 0.01). ER-/PR- status also was associated with decreased survival in blacks (HR: 1.391, p < 0.01), but improved survival in Chinese (HR: 0.793, p < 0.01), Filipinos (HR: 0.787, p < 0.01), Japanese (HR: 0.757, p <0.01), AIP (HR: 0.751, p < 0.01), Vietnamese (HR: 0.736, p < 0.01), and Koreans (HR: 0.705, p < 0.01). Compared to the referent NHW, ER+/PR- status in Chinese (HR: 0.765, p < 0.01), Japanese (HR: 0.794, p < 0.01), Filipinos (HR: 0.711, p < 0.01), and Koreans (HR: 0.662, p < 0.05) there was improved survival, while blacks (HR: 1.612, p < 0.01) had decreased survival. Regarding ER-/PR+ status, blacks (HR: 1.464, p < 0.01) had decrease survival, while only Japanese women exhibited improved outcomes (HR: 0.586, p < 0.01) compared to NHW. Conclusions: For ER/PR phenotypes including ER-/PR- tumors, Asian subgroups showed favorable survival outcomes compared to NHW, while poor outcomes were seen in blacks.

Sign in / Sign up

Export Citation Format

Share Document